MENLO PARK, Calif.,
March 3, 2016 /PRNewswire/
-- BioPharmX Corporation (NYSE MKT: BPMX), a specialty
pharmaceutical company focusing on dermatology and women's health,
today announced that it will immediately commence a Phase 2a
clinical study under its U.S. FDA Investigational New Drug (IND)
application for BPX-01, a hydrophilic formulation of the
well-established drug minocycline. This clinical study will
assess effectiveness in reducing the number of acne-causing
bacteria in study patients at four weeks and evaluate the drug's
safety and tolerability. This is the first clinical study in
the clinical development program for BPX-01.
The clinical study will be conducted by KGL Skin Center, a
Philadelphia-based independent
clinical research facility recognized as a leader in clinical
testing of cosmetics, personal care products, over-the-counter and
prescription drugs, and devices for the skin. The principal
investigator is Dr. Stuart Lessin, a
board-certified dermatologist who serves as KGL's medical
director.
The company's preclinical studies have found the unique gel
formulation of minocycline in BPX-01 can deliver the antibiotic to
the layer of skin where the condition develops, suggesting that the
skin penetration needed to reach an efficacious dose in humans
while minimizing systemic exposure is possible.
"We are excited to begin our IND study of BPX-01," said Kin F.
Chan, Ph.D., executive vice president of research and development
at BioPharmX Corporation. "Our nonclinical research has been well
received by the dermatology community."
Most topical antibiotic acne medications available today have
become less effective in killing the acne-causing bacteria or have
difficulties delivering adequate levels of antibiotic to the
epidermis and the pilosebaceous region where acne develops. The
hydrophilic (non-oil based) BPX-01 formulation is designed to
distribute evenly, not be sticky and not occlude or irritate the
skin, an advantage in the treatment of acne.
The American Academy of Dermatology calls acne the "most common
skin condition in the United States," affecting 40 million to 50
million Americans.
About BioPharmX® Corporation
BioPharmX Corporation
(NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical
company, which seeks to provide products through proprietary
platform technologies for prescription, over-the-counter, and
supplement applications in the health and wellness markets,
including dermatology and women's health. To learn more about
BioPharmX, visit www.BioPharmX.com.
Forward-Looking Statements
The information in this
press release contains forward-looking statements and information
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the "safe harbor" created by those
section. This press release contains forward-looking
statements about the company's expectations, plans, intentions, and
strategies, including, but not limited to, statements regarding:
commencement of our Phase 2a study and the effectiveness of the
BPX-01 gel. These forward-looking statements may be identified by
words such as "plan", "expect," "anticipate," "believe," or similar
expressions that are intended to identify such forward-looking
statements. These forward-looking statements involve
risks and uncertainties, as well as assumptions, which, if they do
not fully materialize or prove incorrect, could cause our results
to differ materially from those expressed or implied by such
forward-looking statements. The risks and uncertainties include
those described in the company's filings with the Securities and
Exchange Commission. Given these risks and uncertainties, you
are cautioned not to place undue reliance on such forward-looking
statements. The forward-looking statements included in this
news release are made only as of the date hereof and the company
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as may be required under
applicable securities laws.
BioPharmX is a registered trademark of BioPharmX, Inc.
Photo -
http://photos.prnewswire.com/prnh/20150711/235327LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biopharmx-commences-phase-2-clinical-study-under-us-fda-ind-for-bpx-01-300230004.html
SOURCE BioPharmX Corporation